Verde Science Signs Research and
Development Pact with Institute Of Chemical Technology
LAS VEGAS, NV -- April 08, 2015 -- InvestorsHub NewsWire --
(OTCPK:
VRCI) Verde Science, Inc., a Pharmaceutical Research and
Development Company focused on developing a portfolio of
cannabinoid based prescription medicines to meet patients needs for
a wide range of medical conditions, is pleased to announce the
execution of a definitive Research and Development Agreement with
the Institute of Chemical Technology of Mumbai, India. Under
the terms of the agreement Verde Science researchers and faculty
and staff of the University will cooperate on original research
with the goal of identifying and developing novel pharmaceutical
formulations derived from the marijuana plant for the treatment of
specific medical issues.
The Institute of Chemical Technology (ICT), established in 1933
was granted “deemed University status” in 2008 and offers
undergraduate, masters, and Ph.D. degree programs in various
Chemical Engineering disciplines including the Technology of
Pharmaceutical and Fine Chemicals. ICT awards approximately
100 Ph.D. degrees annually.
“This relationship is a significant development for Verde and
ICT that will fast track the startup of our initial R&D
projects in conjunction with ICT’s prestigious faculty and within
ICT’s scientific infrastructure. Our initial projects will
focus on the development of efficacious formulations with specific
application to the treatment of seizures and pain management,
administered with the use of novel delivery systems. Further, this
marks our initial step toward becoming a leader in scientific
research for the development of advanced formulations of
cannabis-based compounds for medical use.” according to Harp
Sangha, CEO of Verde Science.
Louis Silver, Verde Science Director of Investor Relations,
added, “Many in the medical community have conceded the
effectiveness of medical marijuana for the treatment of certain
medical issues. However, virtually every credible medical
organization has stated that smoking marijuana is deleterious to
health. The Verde Science pharmacological model mitigates the
risks inherent in the traditional use of marijuana by isolating
active ingredients in the marijuana plant and delivering them in
safe, medically acceptable forms.”
About Verde Science, Inc. (OTCPK: VRCI)
Verde Science, Inc. (trading symbol VRCI:OTCPK)
is an early stage pharmaceutical organization that has built a
research team focused on developing a portfolio of cannabinoid
prescription medicines to meet patient needs in a wide range of
medical conditions. Verde’s scientists have identified a number of
promising areas in which to begin its immediate R&D program,
which will initially be based in India. The Verde Science team of
inter-disciplinary researchers includes scientists in Bioprocess
Engineering, Nanotechnology, Molecular Biology, Pharmaceutical
Sciences and Bio-Medical Devices that is focused on a streamlined
approach to the development of innovative treatment protocols aimed
at capturing considerable market share.
Information
For further information please see our investor profile available
on our website:
www.verdescienceinc.com
Louis Silver, Director of Investor Relations
Tel: 1-610-710-1303
lsilver@verdescienceinc.com
Safe Harbor Statements
Certain information contained in this news release constitutes
“forward-looking statements” as such term is used in applicable
United States and Canadian laws. Generally, these forward-looking
statements can be identified by the use of forward-looking
terminology such as “expects” or “does not expect”, “is expected”,
“anticipates” or “does not anticipate”, “plans”, “estimates”,
“intends” or “believes”, or that certain actions, events or results
“may”, “could”, “would”, “might” or “will be taken”, “occur”, or
“be achieved”. Forward-looking statements are based on the
opinions and estimates of management as of the date such statements
are made, and are subject to known and unknown risks, uncertainties
and other factors that may cause the actual results, performance or
achievements of the Company to be materially different from those
expressed or implied by such forward-looking statements. Many of
these factors are beyond the Company’s ability to control or
predict. Important factors that may cause actual results to differ
materially and that could impact the Company and the statements
contained in this news release can be found in the Company’s
filings with the SEC. Such risks and other factors include, among
others, the ability to locate and acquire suitable interests in
alternative medicine manufacturing operations on terms acceptable
to the Company, the availability of financing on acceptable terms,
accidents, labor disputes, acts of God and other risks of the
alternative medicine industry including, without limitation, delays
in obtaining governmental approvals or permits, title disputes or
claims limitations on insurance coverage. The Company believes that
the expectations reflected in the forward-looking statements
included in this news release are reasonable; however, no assurance
can be given that these expectations will prove to be correct, and
such forward-looking statements should not be unduly relied upon.
The Company assumes no obligation to update or supplement any
forward-looking statements whether as a result of new information,
future events or otherwise.